Insulin Delivery Devices Market by Product, End-User

Description

List of Tables

[189 Pages Report] The Insulin Delivery Devices Market size was estimated at USD 28.55 billion in 2023 and expected to reach USD 30.61 billion in 2024, at a CAGR 8.00% to reach USD 48.93 billion by 2030.

Global Insulin Delivery Devices Market

KEY MARKET STATISTICS
Base Year [2023]	USD 28.55 billion
Estimated Year [2024]	USD 30.61 billion
Forecast Year [2030]	USD 48.93 billion
CAGR (%)	8%

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Insulin Delivery Devices Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Insulin Delivery Devices Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Insulin Delivery Devices Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Baxter International Inc, Becton, Dickinson and Company, Biocon Ltd., Braun Melsungen AG, Bristol-Myers Squibb Company, Daiichi Sankyo Company, Ltd., Dr Reddy's Laboratories Ltd, Eli Lilly and Company, F. Hoffmann-La Roche, Ltd., Insulet Corporation, Johnson & Johnson, Medtronic PLC, Merck & Co., Inc., Novo Nordisk A/S, Sanofi SA, Tandem Diabetes Care, Inc., TOPAS Advanced Polymers GmbH, Ypsomed AG, and Zealand Pharma A/S.

Market Segmentation & Coverage

This research report categorizes the Insulin Delivery Devices Market to forecast the revenues and analyze trends in each of the following sub-markets:

Product
- Insulin Injectors
- Insulin Pens
- Insulin Pumps
- Insulin Syringes
End-User
- Homecare
- Hospitals
Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam
- Europe, Middle East & Africa
  - Denmark
  - Egypt
  - Finland
  - France
  - Germany
  - Israel
  - Italy
  - Netherlands
  - Nigeria
  - Norway
  - Poland
  - Qatar
  - Russia
  - Saudi Arabia
  - South Africa
  - Spain
  - Sweden
  - Switzerland
  - Turkey
  - United Arab Emirates
  - United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Insulin Delivery Devices Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Insulin Delivery Devices Market?

3. What are the technology trends and regulatory frameworks in the Insulin Delivery Devices Market?

4. What is the market share of the leading vendors in the Insulin Delivery Devices Market?

5. Which modes and strategic moves are suitable for entering the Insulin Delivery Devices Market?

Product Code: MRR-ED54C46E8A5E

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

4.1. Introduction
4.2. Insulin Delivery Devices Market, by Region

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Growing chronic diseases and adoption of advanced devices for insulin delivery
  - 5.1.1.2. Increasing diabetic & obese population across the globe
  - 5.1.1.3. Rising consumer awareness about the latest insulin delivery devices
- 5.1.2. Restraints
  - 5.1.2.1. High cost of insulin delivery devices and lack of insurance coverage
- 5.1.3. Opportunities
  - 5.1.3.1. Technological advancements in insulin delivery devices
  - 5.1.3.2. Introduction of automated insulin delivery devices
- 5.1.4. Challenges
  - 5.1.4.1. Increasing stringent government rules and complicated product approval process
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter's Five Forces Analysis
- 5.5.1. Threat of New Entrants
- 5.5.2. Threat of Substitutes
- 5.5.3. Bargaining Power of Customers
- 5.5.4. Bargaining Power of Suppliers
- 5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework

6. Insulin Delivery Devices Market, by Product

6.1. Introduction
6.2. Insulin Injectors
6.3. Insulin Pens
6.4. Insulin Pumps
6.5. Insulin Syringes

7. Insulin Delivery Devices Market, by End-User

7.1. Introduction
7.2. Homecare
7.3. Hospitals

8. Americas Insulin Delivery Devices Market

8.1. Introduction
8.2. Argentina
8.3. Brazil
8.4. Canada
8.5. Mexico
8.6. United States

9. Asia-Pacific Insulin Delivery Devices Market

9.1. Introduction
9.2. Australia
9.3. China
9.4. India
9.5. Indonesia
9.6. Japan
9.7. Malaysia
9.8. Philippines
9.9. Singapore
9.10. South Korea
9.11. Taiwan
9.12. Thailand
9.13. Vietnam

10. Europe, Middle East & Africa Insulin Delivery Devices Market

10.1. Introduction
10.2. Denmark
10.3. Egypt
10.4. Finland
10.5. France
10.6. Germany
10.7. Israel
10.8. Italy
10.9. Netherlands
10.10. Nigeria
10.11. Norway
10.12. Poland
10.13. Qatar
10.14. Russia
10.15. Saudi Arabia
10.16. South Africa
10.17. Spain
10.18. Sweden
10.19. Switzerland
10.20. Turkey
10.21. United Arab Emirates
10.22. United Kingdom

11. Competitive Landscape

11.1. FPNV Positioning Matrix
11.2. Market Share Analysis, By Key Player
11.3. Competitive Scenario Analysis, By Key Player

12. Competitive Portfolio

12.1. Key Company Profiles
- 12.1.1. Abbott Laboratories
- 12.1.2. Baxter International Inc
- 12.1.3. Becton, Dickinson and Company
- 12.1.4. Biocon Ltd.
- 12.1.5. Braun Melsungen AG
- 12.1.6. Bristol-Myers Squibb Company
- 12.1.7. Daiichi Sankyo Company, Ltd.
- 12.1.8. Dr Reddy's Laboratories Ltd
- 12.1.9. Eli Lilly and Company
- 12.1.10. F. Hoffmann-La Roche, Ltd.
- 12.1.11. Insulet Corporation
- 12.1.12. Johnson & Johnson
- 12.1.13. Medtronic PLC
- 12.1.14. Merck & Co., Inc.
- 12.1.15. Novo Nordisk A/S
- 12.1.16. Sanofi SA
- 12.1.17. Tandem Diabetes Care, Inc.
- 12.1.18. TOPAS Advanced Polymers GmbH
- 12.1.19. Ypsomed AG
- 12.1.20. Zealand Pharma A/S
12.2. Key Product Portfolio

13. Appendix

13.1. Discussion Guide
13.2. License & Pricing